LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Начало・Списък с акции・Schrodinger Inc

Schrodinger Inc

Затворен

СекторЗдравеопазване

17.41 -0.29

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

17.35

Максимум

17.59

Ключови измерители
By Trading Economics
Приходи	10M -33M
Продажби	-435K 54M
Марж на печалбата	-60.369
Служители	891
EBITDA	10M -31M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+52.12% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-252M 1.3B
Предишно отваряне	17.7
Предишно затваряне	17.41

Настроения в новините

By Acuity

27%

73%

76 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

23.27 / 26.13 Подкрепа & съпротива

Schrodinger Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.11.2025 г., 16:49 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27.11.2025 г., 15:32 ч. UTC

Придобивния, сливания и поглъщания

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27.11.2025 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27.11.2025 г., 23:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.11.2025 г., 16:05 ч. UTC

Пазарно говорене

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27.11.2025 г., 16:04 ч. UTC

Пазарно говорене

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27.11.2025 г., 15:54 ч. UTC

Придобивния, сливания и поглъщания

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27.11.2025 г., 15:44 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27.11.2025 г., 15:43 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27.11.2025 г., 15:42 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27.11.2025 г., 15:41 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27.11.2025 г., 15:11 ч. UTC

Пазарно говорене

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27.11.2025 г., 14:26 ч. UTC

Пазарно говорене

Hermes' Outperformance Gap Could Narrow -- Market Talk

27.11.2025 г., 14:11 ч. UTC

Пазарно говорене

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27.11.2025 г., 14:11 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

27.11.2025 г., 13:35 ч. UTC

Пазарно говорене

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27.11.2025 г., 13:33 ч. UTC

Пазарно говорене

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27.11.2025 г., 13:22 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

27.11.2025 г., 13:22 ч. UTC

Пазарно говорене

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27.11.2025 г., 13:17 ч. UTC

Пазарно говорене

LVMH Should Be Able to Recover Next Year -- Market Talk

27.11.2025 г., 11:13 ч. UTC

Пазарно говорене

European Gas Prices Come Under Pressure -- Market Talk

27.11.2025 г., 11:07 ч. UTC

Печалби

Genting: Positive About Prospects Over Longer Term

27.11.2025 г., 11:06 ч. UTC

Печалби

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27.11.2025 г., 11:04 ч. UTC

Печалби

Genting: International Travel Demand Expected to Remain Resilient

27.11.2025 г., 11:04 ч. UTC

Печалби

Genting: Global Growth Expected to Remain Subdued

27.11.2025 г., 11:04 ч. UTC

Печалби

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27.11.2025 г., 10:59 ч. UTC

Печалби

Genting Bhd 3Q Net Profit Fell 86% on Year

27.11.2025 г., 10:58 ч. UTC

Печалби

Genting Bhd 3Q Rev Rose 14% on Year

27.11.2025 г., 10:56 ч. UTC

Печалби

Genting Bhd 3Q Net MYR30.3M

27.11.2025 г., 10:56 ч. UTC

Печалби

Genting Bhd 3Q EPS MYR0.0079

Сравнение с други в отрасъла

Ценова промяна

Schrodinger Inc Прогноза

Ценова цел

By TipRanks

52.12% нагоре

12-месечна прогноза

Среден 26.5 USD 52.12%

Висок 33 USD

Нисък 21 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Schrodinger Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Schrodinger Inc през последните 3 месеца.

Техническа оценка

By Trading Central

23.27 / 26.13Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

76 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.